Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences is experiencing enhanced investor confidence following the lifting of the partial clinical hold in autoimmune hepatitis (AIH), indicating an improved risk-benefit profile for its therapeutic candidate, Zetomipzomib (KZR-616). The potential full removal of the clinical hold in lupus nephritis (LN) could significantly bolster investor sentiment and facilitate clinical uptake if approved, demonstrating the promising future of Kezar's development pipeline. Overall, these developments suggest a more favorable commercial outlook for Kezar’s product candidates, which may drive positive financial performance in the long term.

Bears say

Kezar Life Sciences Inc. faces challenges with its clinical-stage pipeline, notably the reliance on the success of product candidates like Zetomipzomib and KZR-261, which are subject to the inherent risks of drug development and regulatory approval. Financially, the company has reported ongoing operating losses and relies on additional funding to sustain its operations, raising concerns about its long-term viability without successful commercialization of its therapeutics. Furthermore, heightened competition in the biotech sector could impede Kezar's market position, affecting future revenue potential and investor confidence.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.